Ticker: XBI

SPDR S&P Biotech ETF

Biotech Financial Services Asset Management

Price 150.55

Reco Sell Potential 40 Risk 70 Updated 2026-11-14

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

SPDR S&P Biotech ETF (XBI.US) is an exchange-traded fund that focuses on the biotechnology sector. It provides investors with exposure to a diverse range of biotech companies involved in the development of pharmaceuticals, diagnostics, and other medical technologies. The fund's core products include shares of various biotech firms, and its major revenue sources stem from the performance of these underlying equities. XBI is designed to track the performance of the S&P Biotechnology Select Industry Index, which includes companies of varying market capitalizations within the biotech industry.

Investment Profile

The investment profile of SPDR S&P Biotech ETF is more aligned with growth investors, given its focus on the biotechnology sector, which is characterized by innovation and potential for significant returns. The ETF may appeal to those seeking exposure to high-growth companies, while also presenting a moderate risk profile. Investors should consider their risk tolerance and investment horizon when evaluating this ETF.

Category: Biotech Sector: Financial Services Industry: Asset Management Investment style: Growth Horizon: Medium-term Company type: Large Cap Experience: Basic 6 months

Fundamental metrics (experimental) Updated: 2026-11-12

20d volatility: 2.3%
Dividend yield: 0.3%
last ex-date: 2026-06-22

AI recommendation changes

Date	Before	After	Reason
2026-11-14	Buy	Sell	Negative momentum and high risk overshadow potential upside.
2026-11-10	Sell	Buy	Positive momentum but uncertain fundamentals and market conditions.
2026-11-06	Hold	Sell	Weak momentum and high risk signal caution.
2026-10-21	Sell	Hold	Mixed momentum; cautious due to volatility.
2026-10-19	Buy	Sell	Weak momentum and high risk signal caution.
2026-10-11	Sell	Buy	Mixed performance; cautious outlook amid sector volatility.
2026-10-09	Hold	Sell	Weak momentum and high risk; cautious approach advised.
2026-09-25	Buy	Hold	Weak momentum and high risk; cautious approach advised.
2026-09-23	Sell	Buy	Strong recent performance, but fundamentals are unclear.
2026-09-17	Hold	Sell	Weak momentum and high risk limit upside potential.
2026-09-10	Buy	Hold	Weak momentum and high risk limit upside potential.
2026-09-02	Hold	Buy	Strong momentum but uncertain fundamentals and market signals.
2026-08-29	Buy	Hold	Weak momentum and high risk; uncertain market conditions.
2026-08-09	Hold	Buy	Strong momentum and positive performance trends support growth.
2026-07-13	Buy	Hold	Strong past performance, but current volatility raises concerns.
2026-07-03	—	Buy	Strong momentum and positive price performance indicate growth.

News Page 1 of 1

Analysts recommend buying Biogen (BIIB) shares as breakout signals bullish trend

07/02/2026, 10:36 AM investing recommendation Analysts: analysts biotech SPDR S&P Biotech ETF Biogen Sarepta Therapeutics

Investors should consider Biogen (BIIB) as a promising opportunity in the biotech sector, given its recent technical breakout and potential for significant upside, while also keeping an eye on the broader Bio-Tech ETF (XBI) for safer exposure.